Figure 5 | Laboratory Investigation

Figure 5

From: Inhibition of proteasome by bortezomib causes intracellular aggregation of hepatic serpins and increases the latent circulating form of antithrombin

Figure 5

Time-dependent effects of bortezomib treatment on murine hepatic antithrombin, and α1- antitrypsin. (a). Immunoblotting results of bortezomib treatment for antithrombin, α1-antitrypsin, β-tubulin as loading control, and prothrombin and fibrinogen as controls of other hepatically-secreted proteins. (b). Immunohistochemical results for antithrombin (alone and combined with an amylase-PAS staining) and α1-antitrypsin ( × 100 magnification). Black arrows indicate antithrombin or α1-antitrypsin accumuli/aggregates; white arrows indicate Mallory bodies. (c) Ultrastructural distribution of antithrombin and α1-antitrypsin under transmission electron microscopy as revealed by immunogold labelling ( × 10 000 magnification). Arrows indicate antithrombin and α1-antitrypsin accumuli.

Back to article page